Endocannabinoid system in neurodegenerative disorders
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Most neurodegenerative disorders (NDD s) are characterized by cognitive impairment and other neurological defects. The definite cause of and pathways underlying the progression of these NDD s are not well‐defined. Several mechanisms have been proposed to contribute to the development of NDD s. These mechanisms may proceed concurrently or successively, and they differ among cell types at different developmental stages in distinct brain regions. The endocannabinoid system, which involves cannabinoid receptors type 1 (CB 1R) and type 2 (CB 2R), endogenous cannabinoids and the enzymes that catabolize these compounds, has been shown to contribute to the development of NDD s in several animal models and human studies. In this review, we discuss the functions of the endocannabinoid system in NDD s and converse the therapeutic efficacy of targeting the endocannabinoid system to rescue NDD s. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Missense mutations in the asynuclein (a-syn) gene have been shown to cause autosomal dominant familial PD (Polymeropoulos et al. 1997; Kruger et al. 1998; Zarranz et al. 2004), and it has been suggested that a-syn causes the microglia-mediated inflammatory response in PD (Zhang et al. 2005; Austin…”
BackgroundEpidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110 · cited 1×
“The irreversible loss of the DA-mediated control of striatal function leads to bradykinesia, tremor, and rigidity in PD (de Lau and Breteler 2006; Branchi et al. 2008, 2010; Bartels and Leenders 2009).”
BackgroundAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Microglial M1/M2 polarization and metabolic states
Orihuela, R., McPherson, C. A., & Harry, G. J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13139 · Cited by 2,070 · cited 1×
“CB2R activation has been reported to transform microglial cells from the M1 to the M2 phenotype (Orihuela et al. 2016) and to favor phagocytosis (Mecha et al. 2015).”
BackgroundEndogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 4×
“Activation of CB1Rs or inhibition of endocannabinoid-degrading enzymes [FAAH, MAGL, and alpha/beta-Hydrolase domain containing 6 (ABHD6)] was shown to enhance Ab clearance across the blood-brain barrier through increased expression of the low-density lipoprotein receptor-related protein 1 (LRP1) (Shibata et al. 2000).”
BackgroundInfluentialZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“…et al. 1997; Kruger et al. 1998; Zarranz et al. 2004), and it has been suggested that a-syn causes the microglia-mediated inflammatory response in PD (Zhang et al. 2005; Austin et al. 2006; Thomas et al. 2007; Gao et al. 2008; Klegeris et al. 2008; Reynolds et al. 2008a,b; Aureli et al. 2014).”
BackgroundKatona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 1×
“CB1Rs have been shown to be localized presynaptically on GABAergic interneurons and glutamatergic neurons (Katona et al. 1999, 2001, 2006), and this localization of CB1Rs is consistent with the proposed role of ECs in modulating GABA and glutamate neurotransmission (Ohno-Shosaku et al. 1998, 2000,…”
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“…through activation of microglia in the SN (McGeer et al. 1988) and an increase in TNF-a, IL-1b, IL-2, IL-4, and IL-6 (Ouchi et al. 2005; Gerhard et al. 2006; Taylor et al. 2013), have been suggested to be significant pathogenic factors in sporadic PD, in which they lead to loss of…”
BackgroundThe endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052 · cited 2×
“There is a similar distribution of CB1Rs in humans (Glass et al. 1997; Biegon and Kerman 2001).”
BackgroundCampion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 1×
“Although the existence of familial AD, which shows early onset, has been characterized, this form only accounts for a small proportion of cases (Hardy 1996a,b; Campion et al. 1999; Hardy and Selkoe 2002).”
BackgroundEndocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 1×
“CB1Rs have been shown to be localized presynaptically on GABAergic interneurons and glutamatergic neurons (Katona et al. 1999, 2001, 2006), and this localization of CB1Rs is consistent with the proposed role of ECs in modulating GABA and glutamate neurotransmission (Ohno-Shosaku et al. 1998, 2000,…”
Gulyas, A. I., Cravatt, B. F., Bracey, M. H., Dinh, T. P., Piomelli, D., Boscia, F., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03428.x · Cited by 561
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses
Katona, I., Urbán, G. M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., & Freund, T. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0309-06.2006 · Cited by 511
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432 · cited 1×
“The real cause of sporadic AD is unknown, but numerous risk factors have been identified, including hypercholesterolemia, ischemic stroke, hypertension, the ApoE4 allele and diabetes (Grammas 2011; Carnevale et al. 2016; Hamel et al. 2016).”
BackgroundLastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382 · cited 3×
“Furthermore, another study demonstrated that the genetic ablation of CB2R exacerbated HD and that administration of CB2R-selective agonists reduced striatal neurodegeneration through microglial activation (Palazuelos et al. 2009).”
BackgroundInfluentialIuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361
García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320 · cited 3×
“…>TH activity & >TH mRNA in striatum & substantia nigra Lastres-Becker et al. (2005) CBD Neuroprotection when administered immediately after the lesion Garcia-Arencibia et al. (2007) MSX-3 <Dopaminergic cell death & neuro- inflammation in substantia nigra Cerri et al. (2014) D9-THCV Improved motor…”
BackgroundChemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents
Brenneisen, R. (2007) · Forensic Science And Medicine · doi:10.1007/978-1-59259-947-9_2 · Cited by 251
α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia
Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227 · cited 1×
“…et al. 1997; Kruger et al. 1998; Zarranz et al. 2004), and it has been suggested that a-syn causes the microglia-mediated inflammatory response in PD (Zhang et al. 2005; Austin et al. 2006; Thomas et al. 2007; Gao et al. 2008; Klegeris et al. 2008; Reynolds et al. 2008a,b; Aureli et al. 2014).”
BackgroundSagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres‐Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., et al. (2009) · Glia · doi:10.1002/glia.20838 · Cited by 201
Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice
Aso, E., Sánchez-Pla, A., Vegas-Lozano, E., Maldonado, R., & Ferrer, I. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141014 · Cited by 154 · cited 3×
“The treatment of APP/PS1/ CB2R KO and APP/PS1/CB2R WT mice with D9-THC and cannabidiol (CBD) at a therapeutic dose are effective in rescuing the memory and learning impairments, Ab42 contents in plaques, and astroglial reactivity (Aso et al. 2015), irrespective of the presence or lack of CB2Rs.”
BackgroundMethodSagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147
The potential therapeutic effects of THC on Alzheimer’s disease
Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., Sutherland, K., Nabar, N., & Cai, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140093 · Cited by 121 · cited 3×
“Exposure to a low concentration of D9-THC reduced Ab levels in N2a-variant Ab protein precursor (AbPP) cells and inhibited Ab aggregation by directly interacting with Ab peptide (Cao et al. 2014).”
BackgroundInfluentialJanefjord, E., Mååg, J. L. V., Harvey, B. S., & Smid, S. D. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9984-x · Cited by 118
Cited by
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
The Notch pathway in CNS homeostasis and neurodegeneration
Ho, D. M., Artavanis‐Tsakonas, S., & Louvi, A. (2020) · WIREs Developmental Biology · doi:10.1002/wdev.358 · Cited by 90
Syal, C., Kosaraju, J., Hamilton, L., Aumont, A., Chu, A., Sarma, S. N., Thomas, J., Seegobin, M., Dilworth, F. J., He, L., et al. (2020) · Theranostics · doi:10.7150/thno.44962 · Cited by 42
Emerging Therapeutic Role of PPAR–α in Cognition and Emotions
Nisbett, K. E., & Pinna, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00998 · Cited by 37
“Neurosteroids and the endocannabinoid system are increasing in relevance as themes in the studies of many disorders and diseases (Berardi et al., 2016; Basavarajappa et al., 2017; Rasmusson et al., 2017).”
BackgroundDistinct functions of endogenous cannabinoid system in alcohol abuse disorders
Basavarajappa, B. S., Joshi, V., Shivakumar, M., & Subbanna, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14780 · Cited by 37
Self-citation
Metadata
- Authors
- Basavarajappa, B. S., Shivakumar, M., Joshi, V., & Subbanna, S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2017-07-05
- Volume
- 142
- Issue
- 5
- Pages
- 624-648
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2625733228
- Cited by
- 212
- References
- 33
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.